Please check the following:
- {{error.value}}
FREE membership
FREE membership
Join InvestSMART today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Start your free 15 day trial now' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
OR
Sign up with
Login with
By continuing, you agree to our
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
Looks you are already a member. Please enter your password to proceed
OR
Sign up with
Login with
By continuing, you agree to our
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
OR
Sign up with
Login with
By continuing, you agree to our
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Check your inbox
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Noxopharm Limited (ASX:NOX)
ALERT: Price-sensitive ASX Announcement for NOX
Current share price for NOX : $0.075 -0.021 (-21.88%)+
Release
30 Oct 2025 8:58AM
Price at Release
$0.096
Full Release
Summary
The September 2025 quarterly report for Noxopharm Limited highlights the company's financial activities and clinical progress. Noxopharm has engaged in strategic partnerships, including an agreement with Tezcat to evaluate oligonucleotides. The HERACLES clinical trial, part of the development of the SOF-SKN™ platform, has advanced without safety issues, targeting autoimmune diseases. Financially, the company reported A$935k in cash with A$1.9m net cash outflows for the quarter, alongside significant R&D expenditure. Efforts to extend financial resources include extending convertible notes and securing a loan from 4F Investments Pty Ltd. The company aims to secure additional funding to support ongoing R&D and operations.
Key Points
- Noxopharm signed a Material Transfer Agreement with Tezcat in late 2024.
- Convertible noteholders approved an extension of the maturity date to 2 January 2027.
- HERACLES clinical trial successfully passed through several dosing cohorts with no safety issues.
- Noxopharm's SOF-SKN™ is in development for autoimmune diseases, with a trial showing promising safety results.
- The company had A$935k in cash as of 30 September 2025 and saw A$1.9m in net cash outflows from operating activities during the quarter.
- Noxopharm made research and development payments of A$877k during the quarter.
- Convertible notes with a face value of $2.6m were extended, allowing access to estimated rebate funds of $2.8m.
- 4F Investments Pty Ltd provided an unsecured loan of $1.25m at a 12% interest rate.
- Company continues to seek additional funding opportunities to extend its financial runway.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
